Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2018

View Archived Issues

Sleep is depression's opposite

Novel CRISPR/Cas-mediated rat model of idiosyncratic drug-induced liver injury

First-in-human data presented for AB-023

Aspirin increases lysosomal biogenesis via PPARalpha and decreases amyloid plaque pathology in mice

Motile sperm domain-containing protein 2 promotes breast cancer cell migration and metastasis

Estrogen receptor alpha activation depends on fibronectin-beta1-integrin pathway in breast cancer

Bench and bedside: Phosphatase inhibition sheds ugly duckling status with new platform technology

Beta Cat studies BC-2059 for unresectable desmoid tumors in phase I

Primary endpoints met in phase IIb study of PRX for presbyopia

Phase III study of RHB-104 in Crohn's disease meets primary endpoint

Regenera initiates phase II study of RPh-201 in NAION

Dong-A conducts phase II study with DA-8010 in overactive bladder

First-in-human study investigates CALR exon 9 mutant peptide vaccine in CALR-mutant MPNs

Janssen studies PRMT5 inhibitor JNJ-64619178 in advanced cancers

FDA approves Azedra for pheochromocytoma or paraganglioma

Arcus cleared to begin phase I trial of anti-TIGIT antibody AB-154

Stop-gain variant in GMIP gene tied to Alzheimer's disease pathogenesis

Contactin-2 levels are altered in mild cognitive impairment

ASTRAL-1 study of guadecitabine in AML does not meet coprimary endpoints

Immutep to begin phase II study of eftilagimod alfa with pembrolizumab

Regeneus reports promising first-in-human data for autologous tumor vaccine RGSH-4-K

Phase II study of laquinimod in Huntington's disease does not meet primary endpoint

European Commission approves Aimovig to prevent migraines

HSP27 found as a potential therapeutic target for treating VCID

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...